

BSW Formulary Update – Following APC May 2021 meeting

New and Updated Prescribing Guidelines

- **Updated** - [BSW SCA For ADHD in adults with no other serious mental health co-morbidities](#). [Dexamfetamine](#) has been included as an option for adults. This should be prescribed by brand **Amfexa**® as generic 5mg tablets are not licensed for ADHD. Note use in adults is off-label.
- **New** - [BSW Guidelines for Prescribing of Stoma Appliances](#) Detailed information on appropriate stoma products and quantities for prescribing in primary care. Includes specialist stoma nurse contacts. Work ongoing to build the formulary chapter for stoma and continence products [here](#) and to build this information into GP prescribing systems.

New additions to the BSWformulary

- [Lyumjev® ▼ insulin lispro 100units/mL KwikPen; 100units/mL KwikPen Junior; 100units/mL cartridges; 100units/mL vial](#). [note Lyumjev 200units/ml high strength insulin is NOT included]. **AMBER TLS**
Ultra-rapid acting insulin. Can be initiated in primary care on the recommendation of a specialist where patient fits criteria for use:
 - Type 1 diabetes
 - Pre-existing diabetes in pregnancy (Type 1 or Type 2)
 - Patients with significant post-prandial hyperglycaemia despite the use of a short acting insulin analogue
 - Patients who are unable to give short acting insulin prior to eating, and consequently have significant post-prandial hyperglycaemia.
- [Tresiba® insulin degludec 100unit/mL Penfill cartridges and FlexTouch pre-filled pen](#) added to the paediatric chapter for use in children in line with local Trust pathways. **AMBER TLS**. Note Tresiba® 200units/ml FlexTouch pre-filled pen high strength insulin is NOT included for paediatric patients and should only be used in adults in line with criteria detailed [here](#).
- [Bevespi Aerosphere® glycopyrronium bromide and formoterol fumarate dihydrate in a pMDI device](#). This is the first LABA/LAMA in a pMDI device licensed for COPD. **GREEN TLS**.
- [Trixeo Aerosphere® formoterol fumarate dehydrate and glycopyrronium bromide and budesonide in a pMDI device](#). This is a LABA/LAMA/ICS in a pMDI device licensed for COPD. **GREEN TLS**.
- [Carobel Instant powder 135g and Thixo-D Original powder 375g](#). Gelling/thickening agents added for paediatric use. **AMBER TLS**.

- [Angusta® misoprostol 25 microgram tablets](#). For obstetric indications in line with local Trust policies. **RED TLS**.
- [Doptelet® ▼ avatrombopag 20mg tablets](#). As per [NICE TA626](#). **RED TLS**.
- [Artenusate powder and solvent for IV injection \(Unlic\)](#). For use in line with acute Trust infectious disease guidance. **RED TLS**.
- [Minims povidone iodine 5% eyedrops](#). **RED TLS**.
- [Silver nitrate 75% applicators added to existing entry](#). Note in primary care, patients should be directed to purchase OTC so **RED TLS**.

Changes in TLS

- [Esmya® ulipristal acetate 5mg tablets](#). Reinstated to BSWformulary now the temporary suspension of its license has been lifted but note [further restrictions for use](#) due to serious liver injury. **RED TLS**.

TLS Aligned for BSW

- [Magnesium aspartate sachets](#) and [magnesium glycerophosphate tablets](#) aligned with **GREEN TLS**. The BCAP/Wilts magnesium supplements guidance has been retired now these licensed products are in established use.
- [Omega-3 acid ethyl esters](#) non formulary entry created.

Removed from BSWformulary (products discontinued by manufacturer)

- [Pregnyl® Chorionic gonadotrophin injection](#).
- [Galantamine TABS formulation](#). Discontinued. Note MR caps still available.
- [Repaglinide](#).

Other BSWformulary website updates

- Typographical amendments made to the following **RED TLS** entries as part of formulary website maintenance and/or paediatric chapter review:
[C1 esterase inhibitors](#); [icatibant](#); [mycophenolate IV infusion](#); [erythropoietins](#); [filgotinib](#); [caffeine citrate](#); [sodium bicarbonate injection](#); [phosphate](#); [midazolam for procedural sedation](#); [chloral hydrate](#); [Prostin VR®](#); [Indocid PDA®](#)

What the BSW CCG formulary team are currently working on

- Working to improve the understanding of the definition of the Traffic Light System and initiation of shared care prescribing, to improve engagement and adherence to the BSW formulary across primary and secondary care.
- Reviewing formulary position of Cox-2 inhibitors.
- Updating COPD guidance.
- Reviewing formulary application for Ferric maltol (Ferracru) and proposed pathway for its use.
- Working with AWP on an oral antipsychotic SCA.
- Reviewing the national SCA consultations by RMOC.
- Updating the HRT pathway and reviewing policies on Testosterone in HRT and on use of CGM.
- Updating the BSW primary care antibiotic guidance in line with NICE updates and reviewing TLS and primary care prescribing of rifampicin.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net